Drug Trial Radar · NCT06763965
Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma.
Last checked: Nov 19, 2026Latest source record: Mar 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
30
Planned (sponsor's estimate)
Start
Nov 26, 2024
Primary completion
Jul 31, 2027
Study completion Jul 31, 2027
Sponsor
- Lead sponsor
- Beijing Bio-Targeting Therapeutics Technology Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Jan 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a single-arm, open-label, dose-escalation and dose-expanding Phase Ⅰb/Ⅱ clinical study to evaluate the safety, tolerability, biodistribution characteristics and preliminary efficacy of recombinant human nsIL12 oncolytic adenovirus injection (BioTTT001) in patients with recurrent/progressive high-grade glioma.
Conditions
- Recurrent High-grade Glioma
Interventions
BioTTT001 injectionBiological
BioTTT001 is administered as a multiple Intratumoral injection. The dose groups to be infusion were 1.0×10\^10 viral particle (VP) ,5.0×10\^10 VP and 2.5×10\^11 VP based on the 3+3 dose escalation principle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse eventsTime frame: 28 days within BioTTT001 injection
- DLT、MTD and/or RP2DTime frame: 28 days within BioTTT001 injection
- OS12Time frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sanbo Brain Hospital, Capital Medical University
Beijing, Chaoyang District, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.